Markets:

Overview

News

Currencies

International

Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

20.17 +0.50 (+2.54%)

Streaming Delayed Price Updated: 10:50 AM EDT, Apr 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

September 10, 2025

From Pomerantz LLP

Via GlobeNewswire

Top 3 Health Care Stocks You'll Regret Missing In Q3 ↗

September 09, 2025

Via Benzinga

Is Summit Therapeutics a Buy, Sell, or Hold Now? ↗

September 09, 2025

Western results for ivonescimab aren't lining up with the huge survival benefit measured in China.

Via The Motley Fool

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 08, 2025

Via Benzinga

Retail Traders Flock To Summit Therapeutics After New Cancer Drug Data Shows Survival Gains ↗

September 07, 2025

Via Stocktwits

Gold Moves Higher; Robinhood Shares Jump ↗

September 08, 2025

Via Benzinga

Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch ↗

September 08, 2025

Summit Therapeutics stock crashed Monday after the company's drug failed to meet the bar for overall survival in lung cancer.

Via Investor's Business Daily

Top movers in Monday's pre-market session ↗

September 08, 2025

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences ↗

September 08, 2025

Summit's ivonescimab showed improved survival trends in NSCLC patients with favorable safety, though some results missed statistical significance thresholds.

Via Benzinga

New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

September 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 08, 2025

Via Benzinga

Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket ↗

September 08, 2025

Via Benzinga

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

September 07, 2025

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Gets A $40 Price Target As Guggenheim Says It Likes Stock At $24, Like It Did At $3 ↗

September 04, 2025

The price target of $40 represents an upside of 70% from the stock’s closing price on Wednesday.

Via Stocktwits

Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025

September 03, 2025

From Summit Therapeutics

Via Business Wire

Marvell Technology, eBay, And DexCom Are Among Top 10 Large Cap Losers Last Week (August 25-August 29): Are The Others In Your Portfolio? ↗

August 31, 2025

Marvell, Hormel, and Keurig Dr Pepper led weekly large-cap losers on weak guidance and analyst downgrades.

Via Benzinga

3 No-Brainer Stocks to Buy Right Now ↗

August 31, 2025

Investing in these pharmaceutical stocks is an easy decision.

Via The Motley Fool

Topics World Trade

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst ↗

August 27, 2025

Summit and Akeso report ivonescimab's survival benefit in lung cancer, boosting approval odds and positioning it as a Keytruda challenger.

Via Benzinga

JM Smucker, Baidu And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

August 27, 2025

Via Benzinga

Summit Draws Frenzied Retail Chatter After Akeso Drug Shows Survival Benefit In Lung Cancer; Retail Sees More Upside ↗

August 26, 2025

Analysts at Bernstein called the survival data “a positive surprise,” framing it as Akeso’s biggest catalyst since the drug previously outperformed Merck’s top-selling cancer therapy.

Via Stocktwits

Navigating the Currents: Top Sectors Primed for Growth in Q3 2025

August 27, 2025

The global economy is sailing into Q3 2025 with a blend of cautious optimism and persistent challenges. While a new tariff regime and elevated geopolitical tensions introduce elements of uncertainty,...

Via MarketMinute

Topics Artificial Intelligence Economy Retirement

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up ↗

August 25, 2025

BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 21, 2025

Via Benzinga

3 Fantastic Growth Stocks to Buy in August ↗

August 17, 2025

Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.

Via The Motley Fool

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

August 14, 2025

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

August 11, 2025

From Summit Therapeutics

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 23, 2025

From Pomerantz LLP

Via GlobeNewswire

3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results ↗

July 22, 2025

Via The Motley Fool

This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich ↗

July 21, 2025

Via The Motley Fool

3 Monster Stocks in the Making to Buy Right Now ↗

July 21, 2025

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.